Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1429602 | 0.85 | MAPT (0.51) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL29922078 | 0.85 | MAPT (0.51) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL8347036 | 0.82 | ALOX15 (0.64) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL29629345 | 0.82 | ALOX15 (0.64) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL25666682 | 0.82 | ALOX15 (0.64) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL2375910 | 0.81 | HPGD (0.62) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL5474995 | 0.79 | HPGD (0.60) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL8398733 | 0.79 | KDM4E (0.61) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL32672680 | 0.79 | KDM4E (0.61) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL12490526 | 0.79 | GSK3B (0.43) | ALOX15HPGDCES2GALR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399509-B2 | Glucopyranoside derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399509-B2 | Glucopyranoside derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399509-B2 | Glucopyranoside derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2260051-B1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-20110028414-A1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-02-03 | — | — | US | disclosed |
| US-20110028414-A1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-02-03 | — | — | US | disclosed |
| US-20110028414-A1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-02-03 | — | — | US | disclosed |
| EP-2260051-A1 | GLUCOPYRANOSIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009124638-A1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-6127388-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT1D receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-5998416-A | Piperazine, piperidine and tetrahydropyridine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| EP-0906318-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| EP-0906308-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045426-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT1D RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997045432-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028414-A1 | GLUCOPYRANOSIDE DERIVATIVES | UGGT1, SLC5A1, SLC5A2 | ALOX15 3682/4885HPGD 1126/4885CES2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.